Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

European Journal of Internal Medicine

Volumn 26, Issue 6, 2015, Pages 379-384

  Santus, P ^a   Radovanovic, D ^a   Paggiaro, P ^b   Papi, A ^c   Sanduzzi, A ^d   Scichilone, N ^e   Braido, F ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BUDESONIDE PLUS FORMOTEROL; CYCLIC AMP; FORMOTEROL; SALMETEROL; BRONCHODILATING AGENT; FORMOTEROL FUMARATE; SALMETEROL XINAFOATE;

AIRWAY REMODELING; AIRWAY SMOOTH MUSCLE CELL; ARTICLE; BINDING AFFINITY; BRONCHODILATATION; BRONCHUS MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; HUMAN; LIPOPHILICITY; META ANALYSIS (TOPIC); MUCOCILIARY CLEARANCE; NONHUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; SYSTEMATIC REVIEW (TOPIC); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

BRONCHODILATOR AGENTS; FORMOTEROL FUMARATE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SALMETEROL XINAFOATE; TREATMENT OUTCOME;

EID: 84939254544     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2015.05.001     Document Type: Review

References (82)

1. M. Cazzola, C.P. Page, L. Calzetta, and M.G. Matera Pharmacology and therapeutics of bronchodilators Pharmacol Rev 64 2012 450 504
2. M. Cazzola, L. Calzetta, and M.G. Matera b2-adrenoceptor agonists: current and future direction Br J Pharmacol 163 2011 4 17
3. J. Wang, B. Nie, W. Xiong, and Y. Xu Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis J Clin Pharm Ther 37 2012 204 211
4. Global strategy for the diagnosis, management and prevention of COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014 [Available from: http://www.goldcopd.org/.]
5. S. Suissa, P. Ernst, K.L. Vandemheen, and S.D. Aaron Methodological issues in therapeutic trials of COPD Eur Respir J 31 2008 927 933
6. E.D. Bateman, S.S. Hurd, P.J. Barnes, J. Bousquet, J.M. Drazen, M. FitzGerald, and et al. Global strategy for asthma management and prevention: GINA executive summary Eur Respir J 31 2008 143 178
7. E.D. Bateman, H.A. Boushey, J. Bousquet, W.W. Busse, T.J. Clark, R.A. Pauwels, and et al. GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study Am J Respir Crit Care Med 170 2004 836 844
8. R.A. Pauwels, C.G. Löfdahl, D.S. Postma, A.E. Tattersfield, P. O'Byrne, P.J. Barnes, and et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group N Engl J Med 337 1997 1405 1411
9. Global Strategy for Asthma Management and Prevention Global Initiative for Asthma (GINA) 2014 [Available from: http://www.ginasthma.org/.]
10. F.J. Roux, B. Grandordy, and J.S. Douglas Functional and binding characteristics of long-acting/∼ 2-agonists in lung and heart Am J Respir Crit Care Med 153 1996 1489 1495
11. J. Lötvall Pharmacological similarities and differences between β2-agonists Respir Med 95 2001 S7 S11 [SUPPLEMENT B]
12. G.P. Anderson, A. Lindén, and K.F. Rabe Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7 3 1994 569 578
13. G. Horvath, E.S. Mendes, N. Schmid, A. Schmid, G.E. Conner, N.L. Fregien, and et al. Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airway Pulm Pharmacol Ther 24 2011 654 659
14. A. Tronde, M. Gillen, L. Borgström, J. Lötvall, and J. Ankerst Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD J Clin Pharmacol 48 2008 1300 1308
15. M. Cazzola, C.P. Page, P. Rogliani, and M.G. Matera β2-Agonist therapy in lung disease Am J Respir Crit Care Med 187 2013 690 696
16. K.M. Lulich, R.G. Goldie, and J.W. Paterson b-Adrenoceptor function in asthmatic bronchial smooth muscle Gen Pharmacol 19 1988 307 311
17. C.K. Billington, O.O. Ojo, R.B. Penn, and S. Ito cAMP regulation of airway smooth muscle function Pulm Pharmacol Ther 26 2013 112 120
18. C.K. Billington, and I.P. Hall Novel cAMP signalling paradigms: therapeutic implications for airway disease Br J Pharmacol 166 2012 401 410
19. A.-B. Jeppsson, G. Löfdahl, B. Waldeck, and E. Widmark On the predictive value of experiments I vitro in the evaluation of the effect duration of bronchodilator drugs for local administration Pulm Pharmacol 2 1989 81 85
20. D.W. McGraw, and S.B. Liggett Molecular mechanisms of beta2-adrenergic receptor function and regulation Proc Am Thorac Soc 2 4 2005 292 296
21. Y. Daaka, L.M. Luttrell, and R.J. Lefkowitz Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A Nature 390 6655 1997 Nov 6 88 91
22. K. Pönicke, F. Gröner, I. Heinroth-Hoffmann, and O.E. Brodde Agonist-specific activation of the beta2-adrenoceptor/Gs-protein and beta2-adrenoceptor/Gi-protein pathway in adult rat ventricular cardiomyocytes Br J Pharmacol 147 7 2006 Apr 714 719
23. A. Lindén, A. Bergendal, A. Ullman, B.E. Skoogh, and C.G. Löfdahl Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism Thorax 48 5 1993 May 547 553
24. E. Naline, Y. Zhang, Y. Qian, N. Mairon, G.P. Anderson, B. Grandordy, and et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus Eur Respir J 7 5 1994 May 914 920
25. M. Adner, B. Larsson, J. Säfholm, I. Naya, and A. Miller-Larsson Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea J Pharmacol Exp Ther 333 2010 273 280
26. Kalavantavanich, and Schramm Am J Physiol Lung Cell Mol Physiol 278 2000 L1101 L1111
27. N. Scichilone, M. Contoli, D. Paleari, P. Pirina, A. Rossi, C.M. Sanguinetti, and et al. Assessing and accessing the small airways; implications for asthma management Pulm Pharmacol Ther 26 2013 172 179
28. P. Verdugo, N.T. Johnson, and P.Y. Tam Beta-adrenergic stimulation of respiratory ciliary activity J Appl Physiol 48 1980 868 871
29. M.J. Sanderson, and E.R. Dirksen Mechanosensitive and beta-adrenergic control of the ciliary beat frequency of mammalian respiratory tract cells in culture Am Rev Respir Dis 139 1989 432 440
30. J.L. Devalia, R.J. Sapsford, C. Rusznak, M.J. Toumbis, and R.J. Davies The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells in vitro Pulm Pharmacol 5 1992 257 263
31. G. Piatti, U. Ambrosetti, P. Santus, and L. Allegra Effects of salmeterol on cilia and mucus in COPD and pneumonia patients Pharmacol Res 51 2005 165 168
32. T. Meyer, P. Reitmeir, P. Brand, C. Herpich, K. Sommerer, A. Schulze, and et al. Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD Respir Med 105 6 2011 Jun 900 906 10.1016/j.rmed.2011.02.007 [Epub 2011 Mar 11]
33. S. Edsbäcker, P. Wollmer, O. Selroos, L. Borgström, B. Olsson, and J. Ingelf Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm Pharmacol Ther 21 2 2008 247 258 [Epub 2007 Sep 6]
34. C. Dalby, T. Polanowski, T. Larsson, L. Borgström, S. Edsbäcker, and T.W. Harrison The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial Respir Res 10 2009 Oct 31 104 10.1186/1465-9921-10-104
35. L. Pang, and A.J. Knox Synergistic inhibition by β2-agonists and corticosteroids on tumor necrosis factor-α-induced interleukin-8 release from cultured human airway smooth-muscle cells Am J Respir Cell Mol Biol 23 2000 79 85
36. S.H. Korn, A. Jerre, and R. Brattsand Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells Eur Respir J 17 2001 1070 1077
37. M. Silvestri, L. Fregonese, F. Sabatini, G. Dasic, and G.A. Rossi Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression Eur Respir J 18 2001 139 145
38. F.M. Spoelstra, D.S. Postma, H. Hovenga, J.A. Noordhoek, and H.F. Kauffman Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts Thorax 57 2002 237 241
39. M.R. Edwards, M.W. Johnson, and S.L. Johnston Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells Am J Respir Cell Mol Biol 34 2006 616 624
40. C.L. Skevaki, I. Christodoulou, I.S. Spyridaki, I. Tiniakou, V. Georgiou, P. Xepapadaki, and et al. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus Clin Exp Allergy 39 11 2009 1700 1710
41. Y.A. Bochkov, W.W. Busse, R.A. Brockman-Schneider, M.D. Evans, N.N. Jarjour, C. McCrae, and et al. Budesonide and formoterol effects on rhinovirus replication and epithelial cell cytokine responses Respir Res 14 2013 98
42. K.M. Kassel, T.A. Wyatt, R.A. Panettieri Jr., and M.L. Toews Inhibition of human airway smooth muscle cell proliferation by beta 2-adrenergic receptors and cAMP is PKA independent: evidence for EPAC involvement Am J Physiol Lung Cell Mol Physiol 294 1 2008 Jan L131 L138 [Epub 2007 Nov 9]
43. M. Roth, P.R. Johnson, J.J. Rüdiger, G.G. King, Q. Ge, and J.K. Burgess Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling Lancet 360 9342 2002 Oct 26 1293 1299
44. F. Lamyel, M. Warnken-Uhlich, W.K. Seemann, and K. Mohr The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts Naunyn Schmiedebergs Arch Pharmacol 384 2 2011 Aug 133 145
45. M.M. Kelly, T.M. O'Connor, R. Leigh, J. Otis, and C. Gwozd Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma J Allergy Clin Immunol 125 2 2010 Feb 349 356
46. L. Todorova, E. Gürcan, A. Miller-Larsson, and G. Westergren-Thorsson Lung fibroblast proteoglycan production induced by serum is inhibited by budesonide and formoterol Am J Respir Cell Mol Biol 34 1 2006 Jan 92 100
47. L. Todorova, L. Bjermer, G. Westergren-Thorsson, and A. Miller-Larsson TGFβ-induced matrix production by bronchial fibroblasts in asthma: budesonide and formoterol effects Respir Med 105 9 2011 Sep 1296 1307
48. M. Saetta, G. Turato, F.M. Facchini, L. Corbino, R.E. Lucchini, G. Casoni, and et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis Am J Respir Crit Care Med 156 1997 1633 1639
49. P.J. Barnes Effect of beta-agonists on inflammatory cells J Allergy Clin Immunol 104 1999 S10 S17
50. A. Pesci, B. Balbi, M. Majori, G. Cacciani, S. Bertacco, and P. Alciato Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease Eur Respir J 12 1998 380 386
51. A.T. Hill, D. Bayley, and R.A. Stockley The interrelationship of sputum inflammatory markers in patients with chronic bronchitis Am J Respir Crit Care Med 160 1999 893 898
52. S.J. Szefler, C.K. Edwards 3rd, C. Haslett, N.R. Zahniser, J.A. Miller, and P.M. Henson Effects of cell isolation procedures and radioligand selection on the characterization of human leukocyte b-adrenergic receptors Biochem Pharmacol 36 1987 1589 1597
53. 2-agonists on resident and infiltrating inflammatory cells J Allergy Clin Immunol 110 2002 5282 5290
54. C. Janson, J. Boe, G. Boman, B. Mossberg, and N. Svedmyr Bronchodilator intake and plasma levels on administration for severe acute asthma Eur Respir J 5 1992 80 85
55. H. Kankaanranta, M.A. Lindsay, M.A. Giembycz, X. Zhang, E. Moilanen, and P.J. Barnes Delayed eosinophil apoptosis in asthma J Allergy Clin Immunol 106 2000 77 83
56. K.F. Rabe, M.A. Giembycz, G. Dent, R.S. Perkins, P. Evans, and P. Barnes Salmeterol is a competitive antagonist at beta-2 adrenoceptor - mediating inhibition of respiratory burst in guinea pig eosinophils Eur J Pharmacol 231 1993 305 308
57. C.I. Ezeamuzie, M. al-Hage, and R.N.P. Nwankwoala The effect of salmeterol on human eosinophils is both stimulus- and response-dependent Int J Immunopharmacol 19 1997 421 430
58. C. Ezeamuzie, and M. al-Hage Differential effects of salbutamol and salmeterol on human eosinophil responses J Pharmacol Exp Ther 284 1998 25 31
59. C.I. Ezeamuzie, and M. al-Hage Effects of some anti-asthma drugs on human eosinophil superoxide anions release and degranulation Int Arch Allergy Immunol 115 1998 162 168
60. K. Yasui, N. Kobayashi, T. Yamazaki, K. Agematsu, S. Matsuzaki, S. Nakata, and et al. Differential effects of short-acting - beta 2-agonists on human granulocyte functions Int Arch Allergy Immunol 139 2005 1 8
61. C. Okada, H. Sugiyama, R. Eda, H. Miyagawa, R.J. Hopp, A.K. Bewtra, and et al. Effects of formoterol on superoxide anion generation from bronchoalveolar lavage cells after antigen challenge in guinea pigs Am J Respir Cell Biol 8 1993 509 517
62. P. Santus, C. Buccellati, S. Centanni, F. Fumagalli, P. Busatto, F. Blasi, and et al. Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects Pharmacol Res 66 2012 343 348
63. S. Persdotter, M. Lindahl, M. Malm-Erjefält, K. von Wachenfeldt, S.H. Korn, T. Stevens, and et al. Cooperative inhibitory effects of budesonide and formoterol on eosinophil superoxide production stimulated by bronchial epithelial cell conditioned medium Int Arch Allergy Immunol 143 2007 201 210
64. C. Rossios, Y. To, G. Osoata, M. Ito, P.J. Barnes, and K. Ito Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibition Br J Pharmacol 167 4 2012 Oct 775 786
65. M. Schmidt, and M.C. Michel β2-Adrenergic and glucocorticoid receptor agonist synergism in obstructive airway diseases Mol Pharmacol 80 2011 955 958
66. O. Eickelberg, M. Roth, R. Lörx, V. Bruce, J. Rüdiger, M. Johnson, and et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells J Biol Chem 274 2 1999 Jan 8 1005 1010
67. J. Lovén, N. Svitacheva, A. Jerre, A. Miller-Larsson, and S.H. Korn Anti-inflammatory activity of beta2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor Eur Respir J 30 5 2007 Nov 848 856 [Epub 2007 Jun 27]
68. O.S. Usmani, K. Ito, K. Maneechotesuwan, M. Ito, M. Johnson, P.J. Barnes, and et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy Am J Respir Crit Care Med 172 6 2005 Sep 15 704 712
69. M. Kaur, J.E. Chivers, M.A. Giembycz, and R. Newton Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells Mol Pharmacol 73 1 2008 Jan 203 214
70. N. Rochel, N.H. Chavannes, and M. Miravitlles COPD symptoms in the morning: impact, evaluation and management Respir Res 14 2013 112
71. M. Cazzola, P. Paggiaro, P. Palange, L. Bjermer, P. Ausin, L.-G. Carlsson, and et al. Onset of Action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease. A randomized, placebo-controlled, double-blind, crossover study Clin Drug Investig 32 2012 147 155
72. M. Cazzola, P. Santus, F. Di Marco, P. Carlucci, M. Mondoni, M.G. Matera, and et al. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD Pulm Pharmacol Ther 17 2004 121 125
73. S. Cope, J.F. Donohue, J.P. Jansen, M. Kraemer, G. Capkun-Niggli, F. Buckley, and et al. Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis Respir Res 14 2013 100
74. T. Welte, M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, T. Polanowski, and et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 180 2009 741 750
75. S.D. Aaron, K.L. Vandemheen, D. Fergusson, F. Maltais, and J. Bourbeau Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary a disease: a randomized trial Ann Intern Med 146 8 2007 Apr 17 545 555
76. K.M. Kew, C. Karner, S.M. Mindus, and G. Ferrara Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children Cochrane Database Syst Rev 12 2013 CD009019
77. P. Kuna, M.J. Peters, A.I. Manjra, C. Jorup, I.P. Naya, N.E. Martínez-Jimenez, and et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations Int J Clin Pract 61 5 2007 May 725 736
78. M. Palmqvist, G. Persson, L. Lazer, J. Rosenborg, P. Larsson, and J. Lötvall Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency Eur Respir J 10 11 1997 Nov 2484 2489
79. P.J. Barnes Scientific rationale for using a single inhaler for asthma control Eur Respir J 29 2007 587 595
80. R. Louis, G. Joos, A. Michils, and G. Vandenhoven A comparison of budesonide/formoterol maintenance and reliever therapy vs. convewntional best practice in asthma management Int J Clin Pract 63 2009 1479 1488
81. F. Braido, I. Baiardini, E. Compalati, A. Bordo, and G.W. Canonica Towards the grade of recommendations, assessment, development and evaluation system: methods and results of budesonide/formoterol maintenance and reliever therapy research Curr Opin Allergy Clin Immunol 11 2011 361 374
82. R. Jaeschke, P.M. O'Byrne, F. Mejza, P. Nair, and W. Lesniak The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis Am J Respir Crit Care Med 178 10 2008 Nov 15 1009 1016